LINC02178 drives lung adenocarcinoma progression and serves as a therapeutic target for nanodelivery-based intervention.

ABSTRACT: Gene therapy has garnered significant attention in cancer treatment. Here, we identified the long noncoding RNA LINC02178 as an oncogenic driver in lung adenocarcinoma (LUAD) and developed a nanoparticle-based small interfering RNA delivery system (NPs/2178) targeting this gene, providing novel insights for gene therapy development. Bioinformatics analysis was used to identify LINC02178 as a candidate oncogene and evaluate its clinical value. Subcellular localization of LINC02178 was determined through cytoplasmic/nuclear RNA fractionation coupled withs Reverse transcription quantitative polymerase chain reaction (RT-qPCR). The transfection efficiency of the NPs was assessed using confocal microscopy and RT‒qPCR. The biological toxicity of NPs/2178 was tested via cell Counting Kit-8 (CCK-8

SUBMITTER: Zeng L 

PROVIDER: S-EPMC12603185 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature